What the research found

A large UK Biobank analysis tracked roughly 50,000 people over time and measured their circulating levels of two IGF-binding proteins (IGFBP-1 and IGFBP-2). The study found a striking disconnect: participants with the highest circulating levels of either protein had substantially lower risk of developing type 2 diabetes, but higher risk of cardiovascular events, cardiovascular death, and all-cause mortality.

When the researchers looked at the biomarker patterns, the paradox deepened. People with elevated IGFBPs showed metabolically favorable signatures—lower HbA1c, better triglyceride-to-HDL ratios, and less abdominal fat—yet simultaneously had higher cardiac stress markers (troponin I, NT-proBNP) and structural changes (enlarged cardiac chambers and aorta).

This suggests IGFBP-1 and IGFBP-2 may have complex, tissue-specific effects that don't align with simple protective or harmful narratives.

Why it matters for you

If you're monitoring IGF axis markers as part of metabolic optimization, this finding warrants caution about treating elevated IGFBPs as uniformly "good." High levels may genuinely reduce diabetes risk, but the cardiovascular associations raise questions about whether you should actively aim to elevate them through peptides, training, or supplementation without considering individual cardiac risk factors.

The mismatch between metabolic markers (HbA1c, triglycerides, body composition) and cardiac markers also highlights a real limitation: a favorable lipid panel and lean physique don't guarantee cardiac health. If you're using IGFBP-1 or IGFBP-2 as tracking biomarkers in MyKine, consider whether you're also monitoring cardiac-specific signals—NT-proBNP, troponin, or structural metrics via imaging—rather than relying on metabolic proxies alone.

This is particularly relevant if you're older, have existing cardiovascular risk, or are using protocols designed to maximize growth factors. The study doesn't prove causation, but it does flag a genuine dissociation worth taking seriously.

Caveats

  • Observational association, not causation: Correlation between high IGFBPs and cardiovascular outcomes doesn't prove one causes the other; reverse causality or unmeasured confounding could explain the link.
  • Cross-sectional proteomics: Blood protein levels were measured at a single timepoint; dynamic changes over time aren't captured.
  • UK Biobank demographics: The cohort's age range, ethnicity composition, and baseline health status may not generalize to all populations or age groups.
  • Mechanism unclear: The study identifies the paradox but doesn't explain why IGFBPs associate differently with metabolic vs. cardiac traits—this remains speculative.